These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17153872)

  • 41. [Guidelines of the Pharmaceutical Benefits Board for health economics evaluations. Cost-efficiency analysis from a national perspective].
    Lundin D; Carlsson P; Levin LA; Persson U
    Lakartidningen; 2006 Nov 22-28; 103(47):3716-8. PubMed ID: 17212321
    [No Abstract]   [Full Text] [Related]  

  • 42. Thai health technology assessment guideline development.
    Teerawattananon Y; Chaikledkaew U
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S11-5. PubMed ID: 19253483
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resource allocation and health technology assessment in Australia: views from the local level.
    Gallego G; van Gool K; Kelleher D
    Int J Technol Assess Health Care; 2009 Apr; 25(2):134-40. PubMed ID: 19331706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Attitudes towards priority-setting and rationing in healthcare -- an exploratory survey of Swedish medical students.
    Omar F; Tinghög G; Tinghög P; Carlsson P
    Scand J Public Health; 2009 Mar; 37(2):122-30. PubMed ID: 19141543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The economics of scaling up: cost estimation for HIV/AIDS interventions.
    Kumaranayake L
    AIDS; 2008 Jul; 22 Suppl 1():S23-33. PubMed ID: 18664950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Are economic evaluations and health technology assessments increasingly demanded in times of rationing health services? The case of the Argentine financial crisis.
    Rubinstein A; Belizán M; Discacciati V
    Int J Technol Assess Health Care; 2007; 23(2):169-76. PubMed ID: 17493302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Re: This special issue of AIDS--a mix of recent economic analyses and commentary on how best to distill economic insights to improve HIV/AIDS policies and programmes.
    Marlink R; Forsythe S; Bertozzi SM; Muirhead D; Holmes M; Sturchio J;
    AIDS; 2008 Jul; 22 Suppl 1():S1-4. PubMed ID: 18664940
    [No Abstract]   [Full Text] [Related]  

  • 49. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis and formulary decision making in England: findings from research.
    Williams IP; Bryan S
    Soc Sci Med; 2007 Nov; 65(10):2116-29. PubMed ID: 17698271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Research priorities in health economics and funding for palliative care: views of an international think tank.
    Harding R; Gomes B; Foley KM; Higginson IJ
    J Pain Symptom Manage; 2009 Jul; 38(1):11-4. PubMed ID: 19615622
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ten arguments for a societal perspective in the economic evaluation of medical innovations.
    Jönsson B
    Eur J Health Econ; 2009 Oct; 10(4):357-9. PubMed ID: 19618224
    [No Abstract]   [Full Text] [Related]  

  • 53. [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions].
    Persson U; Ramsberg J
    Lakartidningen; 2007 Oct 17-23; 104(42):3046-50. PubMed ID: 17985712
    [No Abstract]   [Full Text] [Related]  

  • 54. [Quality of life linked to health in medical economic studies].
    Hosseini K
    Soins; 2011 Oct; (759):43-4. PubMed ID: 22145438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Future costs in economic evaluation. A comment on Lee.
    Feenstra TL; van Baal PH; Gandjour A; Brouwer WB
    J Health Econ; 2008 Dec; 27(6):1645-9; discussion 1650-1. PubMed ID: 18823670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The economics of mental health in the workplace: what do we know and where do we go?
    McDaid D
    Epidemiol Psichiatr Soc; 2007; 16(4):294-8. PubMed ID: 18333424
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Guideline implementation for breast healthcare in low- and middle-income countries: breast healthcare program resource allocation.
    Harford J; Azavedo E; Fischietto M;
    Cancer; 2008 Oct; 113(8 Suppl):2282-96. PubMed ID: 18837020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The status of health economic evaluation within decision making in Austria.
    Zechmeister-Koss I; Stanak M; Wolf S
    Wien Med Wochenschr; 2019 Sep; 169(11-12):271-283. PubMed ID: 30868427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness analysis of establishing a distance-education programme for health personnel in Swaziland.
    Kirigia JM; Sambo LG; Phiri M; Matsembula G; Awases M
    Afr J Health Sci; 2002; 9(1-2):3-15. PubMed ID: 17298141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.